A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): Factors associated with B lymphocyte recovery

被引：52
|
作者：
Sutter, Jennifer A. [1 ,2 ]
Kwan-Morley, Jennifer [3 ]
Dunham, Jon [3 ]
Du, Yang-Zhu [1 ,2 ]
Kamoun, Malek [1 ,2 ]
Albert, Daniel [4 ]
Eisenberg, Robert A. [3 ]
Prak, Eline T. Luning [1 ,2 ]
机构：
[1] Univ Penn, Sch Med, Dept Pathol, Stellar Chance Labs 405B, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Lab Med, Stellar Chance Labs 405B, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA
[4] Dartmouth Hitchcock Med Ctr, Rheumatol Sect, Lebanon, NH 03756 USA
来源：
CLINICAL IMMUNOLOGY | 2008年 / 126卷 / 03期
关键词：
B cells; systemic lupus; erythematosus; autoimmunity; human; transitional B cells; immunophenotype;
D O I：
10.1016/j.clim.2007.11.012
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Identifying factors associated with B lymphocyte depletion and recovery may aid the development of individualized treatment regimens, optimizing therapy for patients with autoimmune disease. In this study, 12 patients with active SLE were monitored at baseline and monthly following treatment with rituximab. The number and phenotype of peripheral blood B lymphocytes, T lymphocytes and natural killer cells were correlated with the extent and longevity of B lymphocyte depletion. This analysis generated three candidate biomarkers for lymphocyte monitoring in patients with autoimmune disease who are treated with rituximab: circulating transitional B cells, the K: ratio and natural killer cells. Further refinement of these potential biomarkers may lead to a better understanding of the rote of B cells in disease pathogenesis and a more rational use of B cell depletion therapies. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码：282 / 290
页数：9
相关论文
共 50 条
  • [21] Risk factors for developing lymphopenia and hypogammaglobulinemia in anti-cd20 treated patients with multiple sclerosis
    Vollmer, B.
    Vollmer, T.
    Corboy, J.
    Alvarez, E.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 304 - 304
  • [22] The polyneuropathy associated with Waldenstrom's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab
    Weide, R
    Heymanns, J
    Köppler, H
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (04) : 838 - 841
  • [23] A longitudinal analysis of SLE patients treated with rituximab: A comparison of B cell depleters to partial B cell depleters
    Dunham, J
    Prak, NL
    Du, YZ
    Goodman, N
    Khan, S
    Albert, D
    Kamoun, M
    Eisenberg, R
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S740 - S740
  • [24] Fcgamma Receptor IIb Facilitates Rapid Internalisation of Rituximab (type 1 anti-CD20 antibody) in B Cells from Patients with RA and SLE and Contributes to Less Efficient B Cell Lysis Than Type 2 Anti-CD20 Antibodies, in Vitro
    Reddy, Venkat
    Cambridge, Geraldine
    Isenberg, David A.
    Cragg, Mark
    Leandro, Maria J.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S440 - S440
  • [25] A longitudinal analysis of transplant recipients treated with rituximab (anti-CD20): B cell ablation is not effective in depleting pre-existing anti-HLA class I or class II antibodies
    Gasiewski, Allison
    Pierce, Erin
    Kearns, Jane
    Prak, Eline Luning
    Goral, Simin
    Doyle, Alden
    Bloom, Roy
    Markmann, James F.
    Miller, Barry
    Jessup, Mariell
    Goldberg, Lee
    Naji, Ali
    Tsai, Donald
    Kamoun, Malek
    HUMAN IMMUNOLOGY, 2006, 67 (10) : S102 - S102
  • [26] Polyneuropathy and vasculitis associated with IgG type I Cryoglobulinemia can be treated effectively with the anti-CD20 monoclonal antibody (Rituximab).
    Rosenthal, E
    Pesce, A
    Karsenti, JM
    Allieri-Rosenthal, MA
    Cassuto, JP
    BLOOD, 2001, 98 (11) : 292B - 292B
  • [27] Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients
    Milpied, N
    Vasseur, B
    Parquet, N
    Garnier, JL
    Antoine, C
    Quartier, P
    Carret, AS
    Bouscary, D
    Faye, A
    Bourbigot, B
    Reguerre, Y
    Stoppa, AM
    Bourquard, P
    de Ligny, BH
    Dubief, F
    Mathieu-Boue, A
    Leblond, V
    ANNALS OF ONCOLOGY, 2000, 11 : 113 - 116
  • [28] Evaluation of Risk Factors in Developing Lymphopenia and Hypogammaglobulinemia in Anti-CD20 Treated Multiple Sclerosis Patients
    Vollmer, Brandi
    Vollmer, Timothy
    Corboy, John
    Alvarez, Enrique
    NEUROLOGY, 2020, 94 (15)
  • [29] Different mechanisms are involved in different organ manifestation in SLE: Learning from treatments with rituximab (anti-CD20) therapy
    Tanaka, Yoshiya
    Tokunaga, Mikiko
    Nawata, Masao
    Iwata, Shigeru
    Nakano, Kazuhisa
    Yamaoka, Kunihiro
    Mima, Tom
    Nishimoto, Norihiro
    Saito, Kazuyoshi
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S568 - S569
  • [30] Effects of the Anti-CD20 Antibody Rituximab on B Cells in Human Secondary Lymphoid Organs
    Kamburova, E.
    Borgman, K.
    Hans, K.
    ten Berge, I
    Joosten, I
    Hilbrands, L.
    TRANSPLANTATION, 2012, 94 (10) : 167 - 167
12345